 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 July 1996 | Volume 125 Issue 1 | Pages 47-58
Purpose: To review the current understanding of the clinical significance, detection, pathogenesis, and prevention of anthracycline-induced cardiotoxicity.
Data Sources: A MEDLINE search of the English-language medical literature and a manual search of the bibliographies of relevant articles, including abstracts from national cardiology meetings.
Study Selection: Pertinent clinical and experimental studies addressing the clinical relevance, pathogenesis, detection, and prevention of anthracycline cardiotoxicity were selected from peer-reviewed journals without judgments about study design. A total of 137 original studies and 9 other articles were chosen.
Data Extraction: Data quality and validity were assessed by each author independently. Statistical analysis of combined data was inappropriate given the differences in patient selection, testing, and follow-up in the available studies.
Data Synthesis: Anthracycline-induced cardiotoxicity limits effective cancer chemotherapy by causing early cardiomyopathy, and it can produce late-onset ventricular dysfunction years after treatment has ceased. Detection of subclinical anthracycline-induced cardiomyopathy through resting left ventricular ejection fraction or echocardiographic fractional shortening is suboptimal. Conventional doses of anthracycline often lead to permanent myocardial damage and reduced functional reserve. Underlying pathogenetic mechanisms may include free-radical-mediated myocyte damage, adrenergic dysfunction, intracellular calcium overload, and the release of cardiotoxic cytokines. Dexrazoxane is the only cardioprotectant clinically approved for use against anthracyclines, and it was only recently introduced for selected patients with breast cancer who are receiving anthracycline therapy.
Conclusions: A rapidly growing number of persons, including an alarming fraction of the 150 000 or more adults in the United States who have survived childhood cancer, will have substantial morbidity and mortality because of anthracycline-related cardiac disease. The development of effective protection against anthracycline-induced cardiotoxicity will probably have a significant effect on the overall survival of these patients.
Author and Article Information
From The Cleveland Clinic Foundation, Cleveland, Ohio.
REVIEW
Anthracycline-Induced Cardiotoxicity
Requests for Reprints: A. Michael Lincoff, MD, Director, Experimental Interventional Laboratory, Department of Cardiology, F25, The Cleveland Clinic Foundation 9500 Euclid Avenue, Cleveland, OH 44195.
Current Author Addresses: Dr. Shan: Baylor College of Medicine, Section of Cardiology, 6550 Fannin MS SM 677, Houston, TX 77030. Drs Lincoff and Young: Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Clevelane, OH 44195.
This article has been cited by other articles:
|
|
 |
|
  J. M. Horacek, M. Tichy, R. Pudil, and L. Jebavy Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity Ann. Onc., September 1, 2008; 19(9): 1656 - 1657. [Full Text] [PDF]
|
|
|
|
 |
|
 T Chung, W-C Lim, R Sy, I Cunningham, J Trotman, and L Kritharides Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function Heart, July 1, 2008; 94(7): 911 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. S. Bains, R. H. Takahashi, T. A. Pfeifer, T. A. Grigliatti, R. E. Reid, and K. W. Riggs Two Allelic Variants of Aldo-Keto Reductase 1A1 Exhibit Reduced in Vitro Metabolism of Daunorubicin Drug Metab. Dispos., May 1, 2008; 36(5): 904 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Huang, S. Duan, E. O. Kistner, W. K. Bleibel, S. M. Delaney, D. L. Fackenthal, S. Das, and M. E. Dolan Genetic Variants Contributing to Daunorubicin-Induced Cytotoxicity Cancer Res., May 1, 2008; 68(9): 3161 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G Marchese, B. H Connolly, C. Able, A. R Booten, P. Bowen, B. M Porter, S. N Rai, M. L Hancock, C.-H. Pui, S. Howard, et al. Relationships Among Severity of Osteonecrosis, Pain, Range of Motion, and Functional Mobility in Children, Adolescents, and Young Adults With Acute Lymphoblastic Leukemia Physical Therapy, March 1, 2008; 88(3): 341 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Shankar, N. Marina, M. M. Hudson, D. C. Hodgson, M. J. Adams, W. Landier, S. Bhatia, K. Meeske, M. H. Chen, K. E. Kinahan, et al. Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group Pediatrics, February 1, 2008; 121(2): e387 - e396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jannazzo, J. Hoffman, and M. Lutz Monitoring of Anthracycline-Induced Cardiotoxicity Ann. Pharmacother., January 1, 2008; 42(1): 99 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bien, A. Riad, C. A. Ritter, M. Gratz, F. Olshausen, D. Westermann, M. Grube, T. Krieg, S. Ciecholewski, S. B. Felix, et al. The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy Cancer Res., November 1, 2007; 67(21): 10428 - 10435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Panjrath, V. Patel, C. I. Valdiviezo, N. Narula, J. Narula, and D. Jain Potentiation of Doxorubicin Cardiotoxicity by Iron Loading in a Rodent Model J. Am. Coll. Cardiol., June 26, 2007; 49(25): 2457 - 2464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Rudzinski, M. Ciesielczyk, W. Religa, Z. Bednarkiewicz, and M. Krzeminska-Pakula Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator Europace, May 1, 2007; 9(5): 278 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Venkatesh, B. Shantala, G. C. Jagetia, K. K. Rao, and M. S. Baliga Modulation of Doxorubicin-Induced Genotoxicity by Aegle marmelos in Mouse Bone Marrow: A Micronucleus Study Integr Cancer Ther, March 1, 2007; 6(1): 42 - 53. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Cardinale, A. Colombo, M. T. Sandri, G. Lamantia, N. Colombo, M. Civelli, G. Martinelli, F. Veglia, C. Fiorentini, and C. M. Cipolla Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition Circulation, December 5, 2006; 114(23): 2474 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Piekarz, A. R. Frye, J. J. Wright, S. M. Steinberg, D. J. Liewehr, D. R. Rosing, V. Sachdev, T. Fojo, and S. E. Bates Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma. Clin. Cancer Res., June 15, 2006; 12(12): 3762 - 3773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Combs, N. Neil, and D. M. Aboulafia Liposomal Doxorubicin, Cyclophosphamide, and Etoposide and Antiretroviral Therapy for Patients with AIDS-Related Lymphoma: A Pilot Study. Oncologist, June 1, 2006; 11(6): 666 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Horan, M. F. McMullin, and P. P. McKeown Anthracycline cardiotoxicity Eur. Heart J., May 2, 2006; 27(10): 1137 - 1138. [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Moser, E. M. Noordijk, F. E. van Leeuwen, S. le Cessie, J. W. Baars, J. Thomas, P. Carde, J. H. Meerwaldt, M. van Glabbeke, and H. C. Kluin-Nelemans Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma Blood, April 1, 2006; 107(7): 2912 - 2919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tassan-Mangina, D. Codorean, M. Metivier, B. Costa, C. Himberlin, C. Jouannaud, A. M. Blaise, J. Elaerts, and P. Nazeyrollas Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study Eur J Echocardiogr, March 1, 2006; 7(2): 141 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Spallarossa, P. Altieri, S. Garibaldi, G. Ghigliotti, C. Barisione, V. Manca, P. Fabbi, A. Ballestrero, C. Brunelli, and A. Barsotti Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase Cardiovasc Res, February 15, 2006; 69(3): 736 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E De Caro, F Fioredda, M G Calevo, A Smeraldi, M Saitta, G Hanau, M Faraci, F Grisolia, G Dini, G Pongiglione, et al. Exercise capacity in apparently healthy survivors of cancer Arch. Dis. Child., January 1, 2006; 91(1): 47 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wojnowski, B. Kulle, M. Schirmer, G. Schluter, A. Schmidt, A. Rosenberger, S. Vonhof, H. Bickeboller, M. R. Toliat, E.-K. Suk, et al. NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity Circulation, December 13, 2005; 112(24): 3754 - 3762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Doyle, A. I. Neugut, J. S. Jacobson, V. R. Grann, and D. L. Hershman Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study J. Clin. Oncol., December 1, 2005; 23(34): 8597 - 8605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mrozek, C. A. Rhoades, J. Allen, E. M. Hade, and C. L. Shapiro Phase I trial of liposomal encapsulated doxorubicin (MyocetTM; D-99) and weekly docetaxel in advanced breast cancer patients Ann. Onc., July 1, 2005; 16(7): 1087 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Hayek, E. Speakman, and E. Rehmus Acute Doxorubicin Cardiotoxicity N. Engl. J. Med., June 9, 2005; 352(23): 2456 - 2457. [Full Text] [PDF]
|
|
|
|
|
|
S. Kilickap, I. Barista, E. Akgul, K. Aytemir, S. Aksoyek, S. Aksoy, I. Celik, S. Kes, and G. Tekuzman cTnT can be a useful marker for early detection of anthracycline cardiotoxicity Ann. Onc., May 1, 2005; 16(5): 798 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pentheroudakis and N. Pavlidis Juvenile cancer: improving care for adolescents and young adults within the frame of medical oncology Ann. Onc., February 1, 2005; 16(2): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kilickap, E. Akgul, S. Aksoy, K. Aytemir, and I. Barista Doxorubicin-induced second degree and complete atrioventricular block Europace, January 1, 2005; 7(3): 227 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chan, N. Davidson, E. Juozaityte, F. Erdkamp, A. Pluzanska, N. Azarnia, and L. W. Lee Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer Ann. Onc., October 1, 2004; 15(10): 1527 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Briasoulis, G. Pentheroudakis, V. Karavasilis, E. Tzamakou, D. Rammou, and N. Pavlidis Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors Ann. Onc., October 1, 2004; 15(10): 1566 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Perez, V. J. Suman, N. E. Davidson, P. A. Kaufman, S. Martino, S. R. Dakhil, J. N. Ingle, R. J. Rodeheffer, B. J. Gersh, and A. S. Jaffe Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial J. Clin. Oncol., September 15, 2004; 22(18): 3700 - 3704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Jung, H. H. Kim, S. H. Park, S. W. Song, M. H. Chung, H. S. Kim, K. J. Kim, M. I. Ahn, S. B. Seo, and S. T. Hahn Thoracic Manifestations of Breast Cancer and Its Therapy RadioGraphics, September 1, 2004; 24(5): 1269 - 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cardinale, M. T. Sandri, A. Colombo, N. Colombo, M. Boeri, G. Lamantia, M. Civelli, F. Peccatori, G. Martinelli, C. Fiorentini, et al. Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy Circulation, June 8, 2004; 109(22): 2749 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Hequet, Q.H. Le, I. Moullet, E. Pauli, G. Salles, D. Espinouse, C. Dumontet, C. Thieblemont, P. Arnaud, D. Antal, et al. Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults J. Clin. Oncol., May 15, 2004; 22(10): 1864 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H.B. Wu, M. Packer, A. Smith, R. Bijou, D. Fink, J. Mair, L. Wallentin, N. Johnston, C. S. Feldcamp, D. M. Haverstick, et al. Analytical and Clinical Evaluation of the Bayer ADVIA Centaur Automated B-Type Natriuretic Peptide Assay in Patients with Heart Failure: A Multisite Study Clin. Chem., May 1, 2004; 50(5): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Van Mieghem, M. Sabbe, and D. Knockaert The Clinical Value of the ECG in Noncardiac Conditions Chest, April 1, 2004; 125(4): 1561 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kattlove and R. J. Winn Ongoing Care of Patients After Primary Treatment for Their Cancer CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Limat, K. Demesmay, L. Voillat, Y. Bernard, E. Deconinck, A. Brion, A. Sabbah, M. C. Woronoff-Lemsi, and J. Y. Cahn Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma Ann. Onc., February 1, 2003; 14(2): 277 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kim, H. Sikder, and K. K. Singh A colony color method identifies the vulnerability of mitochondria to oxidative damage Mutagenesis, September 1, 2002; 17(5): 375 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Childs, S. L. Phaneuf, A. J. Dirks, T. Phillips, and C. Leeuwenburgh Doxorubicin Treatment in Vivo Causes Cytochrome c Release and Cardiomyocyte Apoptosis, As Well As Increased Mitochondrial Efficiency, Superoxide Dismutase Activity, and Bcl-2:Bax Ratio Cancer Res., August 15, 2002; 62(16): 4592 - 4598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M T Meinardi, W T A van der Graaf, J A Gietema, M P van den Berg, D T Sleijfer, E G E de Vries, J Haaksma, F Boomsma, and D J van Veldhuisen Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques Heart, July 1, 2002; 88(1): 81 - 82. [Full Text] [PDF]
|
|
|
|
|
|
B. V. Jensen, T. Skovsgaard, and S. L. Nielsen Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients Ann. Onc., May 1, 2002; 13(5): 699 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nakamura, H. Sugumi, A. Yamaguchi, T. Uenaka, Y. Kotake, T. Okada, J. Kamata, J. Niijima, T. Nagasu, N. Koyanagi, et al. Antitumor Activity of ER-37328, a Novel Carbazole Topoisomerase II Inhibitor Mol. Cancer Ther., January 1, 2002; 1(3): 169 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Levade, N. Auge, R. J. Veldman, O. Cuvillier, A. Negre-Salvayre, and R. Salvayre Sphingolipid Mediators in Cardiovascular Cell Biology and Pathology Circ. Res., November 23, 2001; 89(11): 957 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Shapiro and A. Recht Side Effects of Adjuvant Treatment of Breast Cancer N. Engl. J. Med., June 28, 2001; 344(26): 1997 - 2008. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Darko, A. L Smith, E. L King, and S. J Grethlein Mitoxantrone-induced cardiotoxicity Journal of Oncology Pharmacy Practice, March 1, 2001; 7(1): 47 - 48. [Abstract] [PDF]
|
|
|
|
|
|
C. Geroni, M. Ripamonti, C. Arrigoni, F. Fiorentini, L. Capolongo, D. Moneta, S. Marchini, P. D. Torre, C. Albanese, M. G. Lamparelli, et al. Pharmacological and Toxicological Aspects of 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): A Novel Antineoplastic Agent Cancer Res., March 1, 2001; 61(5): 1983 - 1990. [Abstract] [Full Text]
|
|
|
|
|
|
M. Zambetti, A. Moliterni, C. Materazzo, M. Stefanelli, S. Cipriani, P. Valagussa, G. Bonadonna, and L. Gianni Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation J. Clin. Oncol., January 1, 2001; 19(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C.M. Kremer, E. C. van Dalen, M. Offringa, J. Ottenkamp, and P. A. Voute Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study J. Clin. Oncol., January 1, 2001; 19(1): 191 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Burstein and E. P. Winer Primary Care for Survivors of Breast Cancer N. Engl. J. Med., October 12, 2000; 343(15): 1086 - 1094. [Full Text] [PDF]
|
|
|
|
|
|
G. L. Forrest, B. Gonzalez, W. Tseng, X. Li, and J. Mann Human Carbonyl Reductase Overexpression in the Heart Advances the Development of Doxorubicin-induced Cardiotoxicity in Transgenic Mice Cancer Res., September 1, 2000; 60(18): 5158 - 5164. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Kimura, I. Fujita, N. Itoh, N. Muto, T. Nakanishi, K. Takahashi, J. Azuma, and K. Tanaka Metallothionein Acts as a Cytoprotectant against Doxorubicin Toxicity J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 299 - 302. [Abstract] [Full Text]
|
|
|
|
|
|
T. W. Cheung, S. C. Remick, N. Azarnia, J. A. Proper, J. R. Barrueco, and B. J. Dezube AIDS-related Kaposi's Sarcoma: A Phase II Study of Liposomal Doxorubicin Clin. Cancer Res., November 1, 1999; 5(11): 3432 - 3437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, et al. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease J. Clin. Oncol., September 1, 1999; 17(9): 2639 - 2639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. ANDRIEU-ABADIE, J.-P. JAFFRÉZOU, S. HATEM, G. LAURENT, T. LEVADE, and J.-J. MERCADIER L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation FASEB J, September 1, 1999; 13(12): 1501 - 1510. [Abstract] [Full Text]
|
|
|
|
|
|
E. Delpy, S. N Hatem, N. Andrieu, C. de Vaumas, M. Henaff, C. Rucker-Martin, J.-P. Jaffrezou, G. Laurent, T. Levade, and J.-J. Mercadier Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes Cardiovasc Res, August 1, 1999; 43(2): 398 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Hashimoto, F. Ichida, M. Miura, T. Okabe, H. Kanegane, K.-i. Uese, Y. Hamamichi, T. Misaki, S. Koizumi, and T. Miyawaki Automatic Border Detection Identifies Subclinical Anthracycline Cardiotoxicity in Children With Malignancy Circulation, May 11, 1999; 99(18): 2367 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Valero, A. U. Buzdar, R. L. Theriault, N. Azarnia, G. A. Fonseca, J. Willey, M. Ewer, R. S. Walters, B. Mackay, D. Podoloff, et al. Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1425 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Shapiro, T. Ervin, L. Welles, N. Azarnia, J. Keating, and D. F. Hayes Phase II Trial of High-Dose Liposome-Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer J. Clin. Oncol., April 1, 1999; 17(5): 1435 - 1435. [Abstract] [Full Text] [PDF]
|
|
Article
